It is now clear to me that both you and Beareclawe are on this board with ulterior motives that are not in the best interest of the science and afflicted. You are correct that this is not an investment (yet) but neither was Microsoft not Apple until viable commercialization. The negatives that you and Bear continually bring up are in the past. This is no Genta. But whether it pays off or not will be determined within the next 12 to 24 months.
I think OCATA desperately needs a JV partner for both credibility and program expense participation. That no big pharma partner has been brought in is disturbing. IMO this is because either management is too greedy or think too highly of their own capabilities or potential JV partners are not convinced of the risk/return metrics, or the right JV is being worked on and will be formalized and announced within the next 3 months. All the more reason to understand that this is a speculation and not an investment.
Cam, until Ocat is on a definable path to commercialize it is a big speculation ( not an investment). Today the science is still not 100% defined and the science as a treatment has not been officially (FDA/EMA) sanctioned. Personally I believe in the science and in the probability for the success of commercialization, but the longer it takes to get there the lower the payback will be for those currently holding shares. if developments lead to a quicker path to commercialization you will regret not holding shares but otherwise you should only put at risk what you can comfortably afford to lose here. The best of luck to all Ocat longs and to the success of this company!
Read the transcript of the Wooten presentation (at Cantor seminar). All I can say is wow...........and also that the person in charge of OCAT publicity should be fired for no press release of successful share raise.
Is the lack of news of subscription sell-out (with over allotment) an indication of only a partial subscription? Is this info available to us peon shareholders?
Just ask the jellyfish and the lobster, no death gene, live fore-ever (just look out for natural predators and don't step on a hidden rollerskate :)
Loner, is this just an assumption on your part or do you have some substantiation which would extend some credibility into your above scenario!?
I am also a long time holder/accumulator of this stock. However this is a speculation and should be a small part of a risk controlled portfolio. Good luck to us and to all of the folks that need this science and this company to succeed .
Wanting shares in strong institutional hands is not a reason to sequence news in a manner that is non-supportive for fund raise pricing. In addition, no positive news release prior to fund raise and new proposed management stock incentive program is not logical if it is coming from a position of strength!
If positive news on the other patients, etc is internally known, why wouldn't management release that news prior to this fund raise in order to achieve higher pricing? Is the intention to shake out the little guy, because the approach, along with the newly proposed share incentive program for management does not seem to come from a position of strength?
Right on target Mr User!
Agree with you 1000%
Senior officer "bonus" compensation in a public company should always be a function of performance with set goal achievement. This is not a privately held company where "entitlement" determines the benefit & compensation hierarchy.
As a shareholder I am more than willing to "share" but management must now show me the money also!
I totally agree. As a shareholder it is now time for management to "show me the money" then, and only then, will they be entitled to a next incentive bonus!